Karyopharm Therapeutics, Inc. (KPTI)
0.8022
-0.06
(-7.45%)
USD |
NASDAQ |
Oct 02, 16:00
0.8487
+0.05
(+5.80%)
After-Hours: 20:00
Karyopharm Therapeutics Net Income (Quarterly) : -67.02M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -67.02M |
| March 31, 2026 | -22.39M |
| December 31, 2025 | -102.20M |
| September 30, 2025 | -33.13M |
| June 30, 2025 | -37.25M |
| March 31, 2025 | -23.46M |
| December 31, 2024 | -30.78M |
| September 30, 2024 | -32.07M |
| June 30, 2024 | 23.79M |
| March 31, 2024 | -37.36M |
| December 31, 2023 | -41.84M |
| September 30, 2023 | -34.51M |
| June 30, 2023 | -32.63M |
| March 31, 2023 | -34.13M |
| December 31, 2022 | -38.51M |
| September 30, 2022 | -36.32M |
| June 30, 2022 | -49.06M |
| March 31, 2022 | -41.40M |
| December 31, 2021 | 38.72M |
| September 30, 2021 | -51.81M |
| June 30, 2021 | -53.58M |
| March 31, 2021 | -57.41M |
| December 31, 2020 | -43.42M |
| September 30, 2020 | -53.50M |
| June 30, 2020 | -46.43M |
| Date | Value |
|---|---|
| March 31, 2020 | -52.93M |
| December 31, 2019 | -48.65M |
| September 30, 2019 | -41.37M |
| June 30, 2019 | -43.42M |
| March 31, 2019 | -66.16M |
| December 31, 2018 | -58.21M |
| September 30, 2018 | -48.08M |
| June 30, 2018 | -33.66M |
| March 31, 2018 | -38.46M |
| December 31, 2017 | -39.04M |
| September 30, 2017 | -30.64M |
| June 30, 2017 | -29.39M |
| March 31, 2017 | -29.92M |
| December 31, 2016 | -26.94M |
| September 30, 2016 | -25.42M |
| June 30, 2016 | -30.16M |
| March 31, 2016 | -27.06M |
| December 31, 2015 | -29.05M |
| September 30, 2015 | -30.37M |
| June 30, 2015 | -32.70M |
| March 31, 2015 | -26.07M |
| December 31, 2014 | -25.93M |
| September 30, 2014 | -19.72M |
| June 30, 2014 | -16.43M |
| March 31, 2014 | -13.69M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Madrigal Pharmaceuticals, Inc. | -57.94M |
| Relay Therapeutics, Inc. | -83.71M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Savara, Inc. | -40.23M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 33.43M |
| Total Expenses (Quarterly) | 100.46M |
| EPS Diluted (Quarterly) | -2.316 |
| Enterprise Value | 209.28M |
| Gross Profit Margin (Quarterly) | 96.75% |
| Profit Margin (Quarterly) | -200.5% |
| Earnings Yield | -1.63K% |
| Normalized Earnings Yield | -1326.76 |